22

Endothelial progenitor cells (EPCs) can be used to treat ischemic disease in cell-based therapy owing to their neovascularization potential. Glucocorticoids (GCs) have been widely used as strong anti-inflammatory agent for various kinds of diseases such as autoimmune disorder, inflamantory condition, and also heart failure. However, despite their beneficial effects, side effects, such as impairing wound healing are commonly reported with GC-based therapy, I recent study showed in heart diseases, but the effects of GC on the wound healing function of EPCs are unclear.

Stem Cell and Cancer Institute invited Erica Carolina as a speaker, in this occasion Erica shared her expertise and experiences of this topic, in which she was involved in. Her group investigated how GC treatment could affects the characteristics and wound healing function of EPCs. She explained interaction between GC and EPCs could alter EPCs CXCR4 expression and its wound healing ability , suggesting that the use of EPCs for autologous cell transplantation in patients who have taken GCs for a period of time should be considered carefully.



Figure 1. Erica Shared knowledge about Glucocorticoid Impared the Wound Healing Ability of Endothelial Progenitor Cells by Reducing the Expression of CXCR4 in the PGE2 Pathway.


Figure 2. left to right : Indra Bachtiar Ph.D, dr. Boenjamin S, Ahmad Utomo Ph.D, Erica Carolina, dr Sandy Qlintang, Dr. Harry Murti.

Post Rating

Comments

There are currently no comments, be the first to post one.

Post Comment

Only registered users may post comments.

News & Events

SCAN

Events

SCI - Events

Stem Cell News

Cell Therapy News

Cancer News

Internship Program